RATIONALE: Patients treated with peroxisome proliferator-activated receptor (PPAR)-gamma agonist manifest favorable metabolic profiles associated with increased plasma adiponectin (APN). However, whether increased APN production as a result of PPAR-gamma agonist treatment is an epiphenomenon or is causatively related to the cardioprotective actions of PPAR-gamma remains unknown. OBJECTIVE: To determine the role of APN in rosiglitazone (RSG) cardioprotection against ischemic heart injury. METHODS AND RESULTS: Adult male wild-type (WT) and APN knockdown/knockout (APN(+ or -) and APN(- or -)) mice were treated with vehicle or RSG (20 mg/kg per day), and subjected to coronary artery ligation 3 days after beginning treatment. In WT mice, RSG (7 days) significantly increased adipocyte APN expression, elevated plasma APN levels (2.6-fold), reduced infarct size (17% reduction), decreased apoptosis (0.23 + or - 0.02% versus 0.47 + or - 0.04% TUNEL-positive in remote nonischemic area), attenuated oxidative stress (48.5% reduction), and improved cardiac function (P<0.01). RSG-induced APN production and cardioprotection were significantly blunted (P<0.05 versus WT) in APN(+ or -), and completely lost in APN(- or -) (P>0.05 versus vehicle-treated APN(- or -) mice). Moreover, treatment with RSG for up to 14 days significantly improved the postischemic survival rate of WT mice (P<0.05 versus vehicle group) but not APN knockdown/knockout mice. CONCLUSIONS: The cardioprotective effects of PPAR-gamma agonists are critically dependent on its APN stimulatory action, suggesting that under pathological conditions where APN expression is impaired (such as advanced type 2 diabetes), the harmful cardiovascular effects of PPAR-gamma agonists may outweigh its cardioprotective benefits.
RATIONALE: Patients treated with peroxisome proliferator-activated receptor (PPAR)-gamma agonist manifest favorable metabolic profiles associated with increased plasma adiponectin (APN). However, whether increased APN production as a result of PPAR-gamma agonist treatment is an epiphenomenon or is causatively related to the cardioprotective actions of PPAR-gamma remains unknown. OBJECTIVE: To determine the role of APN in rosiglitazone (RSG) cardioprotection against ischemic heart injury. METHODS AND RESULTS: Adult male wild-type (WT) and APN knockdown/knockout (APN(+ or -) and APN(- or -)) mice were treated with vehicle or RSG (20 mg/kg per day), and subjected to coronary artery ligation 3 days after beginning treatment. In WT mice, RSG (7 days) significantly increased adipocyte APN expression, elevated plasma APN levels (2.6-fold), reduced infarct size (17% reduction), decreased apoptosis (0.23 + or - 0.02% versus 0.47 + or - 0.04% TUNEL-positive in remote nonischemic area), attenuated oxidative stress (48.5% reduction), and improved cardiac function (P<0.01). RSG-induced APN production and cardioprotection were significantly blunted (P<0.05 versus WT) in APN(+ or -), and completely lost in APN(- or -) (P>0.05 versus vehicle-treated APN(- or -) mice). Moreover, treatment with RSG for up to 14 days significantly improved the postischemic survival rate of WT mice (P<0.05 versus vehicle group) but not APN knockdown/knockout mice. CONCLUSIONS: The cardioprotective effects of PPAR-gamma agonists are critically dependent on its APN stimulatory action, suggesting that under pathological conditions where APN expression is impaired (such as advanced type 2 diabetes), the harmful cardiovascular effects of PPAR-gamma agonists may outweigh its cardioprotective benefits.
Authors: Ling Tao; Erhe Gao; Xiangying Jiao; Yuexing Yuan; Shuzhuang Li; Theodore A Christopher; Bernard L Lopez; Walter Koch; Lawrence Chan; Barry J Goldstein; Xin L Ma Journal: Circulation Date: 2007-03-05 Impact factor: 29.690
Authors: Sajoscha A Sorrentino; Ferdinand H Bahlmann; Christian Besler; Maja Müller; Svenja Schulz; Nina Kirchhoff; Carola Doerries; Tibor Horváth; Anne Limbourg; Florian Limbourg; Danilo Fliser; Hermann Haller; Helmut Drexler; Ulf Landmesser Journal: Circulation Date: 2007-06-25 Impact factor: 29.690
Authors: Ruby L C Hoo; W S Chow; M H Yau; A Xu; Annette W K Tso; H F Tse; Carol H Y Fong; Sidney Tam; Lawrence Chan; Karen S L Lam Journal: Arterioscler Thromb Vasc Biol Date: 2007-10-11 Impact factor: 8.311
Authors: Jason M Correnti; Daniel Cook; Edita Aksamitiene; Aditi Swarup; Babatunde Ogunnaike; Rajanikanth Vadigepalli; Jan B Hoek Journal: J Physiol Date: 2015-01-15 Impact factor: 5.182
Authors: Hamid-Reza Kohan-Ghadr; Brian A Kilburn; Leena Kadam; Eugenia Johnson; Bradley L Kolb; Javier Rodriguez-Kovacs; Michael Hertz; D Randall Armant; Sascha Drewlo Journal: Biol Reprod Date: 2019-02-01 Impact factor: 4.285
Authors: Adam Kassan; Uyen Pham; Quynhmy Nguyen; Melissa E Reichelt; Eunbyul Cho; Piyush M Patel; David M Roth; Brian P Head; Hemal H Patel Journal: Am J Physiol Cell Physiol Date: 2016-10-05 Impact factor: 4.249